These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31081461)

  • 1. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
    Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
    Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 7. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
    Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
    J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
    Feldman SR; Zhao Y; Zhou H; Herrera V; Tian H; Li Y
    J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
    Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
    J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
    Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
    Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine: stimulating antidepressant treatment?
    Malhi GS; Byrow Y; Cassidy F; Cipriani A; Demyttenaere K; Frye MA; Gitlin M; Kennedy SH; Ketter TA; Lam RW; McShane R; Mitchell AJ; Ostacher MJ; Rizvi SJ; Thase ME; Tohen M
    BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W; Nordstrom B; Wu JJ; Goldblum O; Solotkin K; Lin CY; Kistler K; Fraeman K; Johnston J; Hawley LL; Sicignano N; Araujo A
    J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
    Ingham M; Sadik K; Zhao X; Song J; Fendrick AM
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1084-1092. PubMed ID: 37548953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.